Annual general meeting of Medigene AG on 24 June 2024
Convenience Translation
Gerd Zettlmeissl, PhD
Year of birth
1955
Current place of residence
Vienna, Austria
Current position(s)
Self-employed consultant immunoprophylaxis and immunotherapies
Other current supervisory
Company
Location
Job title
Conflict of
board
or
nonexecutive
interest
mandates
MSD
Wellcome
New Delhi,
Chairman of the
No
Trust
Hilleman
India
Supervisory
Laboratories
Board
Themis
Vienna,
Chairman of the
No
Bioscience GmbH
Austria
Supervisory
Board
Shareholding in Medigene
☐ None
☒ Yes, 10.000
Personal
/
occupational
☒ None
relationship with Medigene
☐ Yes
or its Management
Relevant
knowledge, skills
More than 25 years of experience in leading positions in both
and experience related to
research & development and management in the international
the Medigene mandate
pharmaceutical and biotech industry with focus on immunological
products
10 years of experience as supervisory board member - mostly as
chairman - in a number of international pharmaceutical and biotech
companies
Professional background
Until early 2015 he was Chairman of the Supervisory Board of GlycoVaxyn (Switzerland), an innovative vaccine company acquired by GlaxoSmithKline and until 2020 Chairman of Themis Bioscience (Austria), a vaccine/immunotherapy company acquired by Merck Shark Dhome. He is the former CEO of the Austrian-based biotechnology company Intercell (now Valneva). While at Intercell from 2001 to 2011, he built the company from a private start-up venture to a publicly listed international organization with more than 400 employees. As CEO, he secured global regulatory approval for and led the launch of an improved Japanese Encephalitis vaccine and oversaw efforts to build and advance a broad-based development portfolio of vaccines. Prior to joining Intercell, Dr. Zettlmeissl was Managing Director of Chiron Behring and held senior management roles in biopharmaceutical R&D and Technical Operations at Chiron Corp. and Behringwerke. In 2010, he was named Vaccine Biotech CEO of the Year at the World Vaccine Congress. Dr. Zettlmeissl holds a doctoral degree in biochemistry of the University of Regensburg and did a post- doctoral fellowship at the Institut Pasteur Paris in virology.
Education
Studies in Biology and Chemistry, University of Regensburg, Germany
Doctorate in Biochemistry, University of Regensburg, Germany
Postdoc, Institut Pasteur, Paris, France
Attachments
Original Link
Original Document
Permalink
Disclaimer
MediGene AG published this content on
17 May 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
17 May 2024 10:18:08 UTC.
Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.
MEDIGENE AG 
